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ABSTRACT 
Background: Schizophrenia is a chronic debilitating disease that affects 
-110,000 Canadians (0.55% lifetime prevalence). Risperidone long-acting injec- 
tion (RLAI) is the first injectable, long-acting, atypical antipsychotic drug mar- 
keted in Canada. 
Objective: The aim of this study was to assess the clinical effectiveness and 
hospitalization rates of patients with schizophrenia, schizoaffective disorder, 
or schizophreniform disorder treated with RLAI in a community mental health 
care setting. 
Methods: Data were collected between August 1, 2006 and September 30, 
2006 via a retrospective chart review of outpatients diagnosed with schizo- 
phrenia, schizoaffective disorder, or schizophreniform disorder who received 
treatment from 1 of the 8 mental health teams within the Vancouver Community 
Mental Health Organization (VCMHO) in Vancouver, British Columbia, Canada. 
Collected ata included: frequency and duration of institutional care, discharge 
and relapse rates, demographic variables, diagnosis history, RLAI medication 
history, and history of other medications. The overall severity of symptoms 
before and after RLAI treatment and the improvement in symptoms during 
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treatment were evaluated using the Clinical Global Impression Scales for severi- 
ty (CGI-S) (1 = not ill to 7 = extremely ill) and improvement (CGI-I) (1 = very much 
improved to 7 = very much worse). 
Results: Forty-four patients were identified as having received RLAI. The 
charts of 19 patients (10 men, 9 women; mean [SD] age at time of chart audit, 
36.7 [11.7] years; mean [SD] age at primary diagnosis, 23.6 [7.4] years; race: 
white, 10 [52.6%]; Asian, 6 [31.6%]; American Indian, 1 [5.3%]; black, 1 [5.3%]; 
other, 1 [5.3%]) were included in the analysis. The majority of patients (78%) 
had been treated with another antipsychotic drug prior to treatment with RLAI: 
risperidone (77%), quetiapine (47%), zuclopenthixol (43%), olanzapine (43%), 
and loxapine (17%). Mean (SD) CGI-S Scale score declined significantly from 
5.29 (1.3) before treatment initiation to 3.05 (1.0) posttreatment (P = 0.001). 
Mean (SD) CGI-I Scale score was 2.58 (0.71) (P < 0.001); 94% of patients had a 
CGI-I score <3. Mean (SD) duration of hospitalization decreased significantly 
from 15.7 (19.7) days before treatment to 2.4 (6.0) days after treatment (P < 
0.05). Mean (SD) number of hospitalizations also decreased significantly from 
2.0 (1.8) before treatment to 0.5 (1.3) after treatment (P < 0.01). 
Conclusions: The results of this pilot study suggest that use of the atypical- 
antipsychotic medication RLAI significantly decreased uration and rates 
of hospitalization, compared with baseline, in these VCMHO patients with 
schizophrenia spectrum illnesses. (Curr Ther Res Clin Exp. 2007;68:409-420) 
Copyright © 2007 Excerpta Medica, Inc. 
Key words: schizophrenia, typical antipsychotics, hospitalization, risperi- 
done long-acting injection, relapse. 
INTRODUCTION 
Schizophrenia s a chronic debilitating disease that affects ~110,000 Canadians 
(0.55% lifetime prevalence). 1,2Schizophrenia often manifests in early adult- 
hood, and the majority of patients (50%-70%) have chronic relapses, with high 
morbidity and above-average mortality. 1,3 Patients with schizophrenia have 
been reported to have an increased risk for suicide, violence, substance abuse, 
homelessness, and victimization. 4 The chronic nature of this disease requires 
continuous management. 
Schizophrenia is characterized by a high rate of relapse. 5 Once relapse 
occurs, hospitalization is usually required to bring symptoms under control. 6,7 
Relapses typically result in poorer mental health outcomes, including higher 
probability of relapse, reduced or delayed likelihood of recovery, and treatment 
refraction for the patient. 5 
Health care costs in schizophrenia are disproportionately high. Although 
the illness affects -1% of the population, it accounts for up to 3% of health 
care expenditure. 8 The high economic ost of schizophrenia is due to the 
nature of the disease, with its early onset, lifetime duration, and, in particu- 
lar, the high rate of hospitalization. 5 Seventy-nine percent of the direct costs 
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of schizophrenia result from hospitalization or other residential care, 9 while 
medications represent only a small fraction (1%-6%) of the total cost. 1° In 
Canada, the total direct and indirect costs for 1 year (1996) were estimated 
to be Can $2.35 billion. 5 Patients who do not adhere to antipsychotic medi- 
cation have high rates of relapse. 1-13 Within 2 years of nonadherence, the 
relapse rate in patients rises to >80%. 14 Risk of relapse over a period of 
6 months to 2 years has been quantified in a review 15 of 7 studies of patients 
with schizophrenia. In that study, patients who were nonadherent to medi- 
cation relapsed at a rate 2.7 times higher than those patients who were 
adherent. Clearly, one of the consequences of relapse is hospitalization; the 
1-year rehospitalization rate for nonadherent patients with schizophrenia 
is ~80%. 13,16,17 
Relapses have an impact on future long-term prognosis and a profound 
impact on a patient's quality of life. 18-2° Each time a patient relapses and 
becomes acutely psychotic, they are unable to return to the same level of 
functioning they experienced before the exacerbation. 21 In addition, with 
each subsequent psychotic episode, the time to remission has been found 
to increase substantially. 22 Consequently, treatment is aimed at preventing 
acute episodes or relapses. 2°,23 However, many factors impact relapse pre- 
vention, including the effectiveness of the drug treatment, he tolerability of 
the drug treatment, and medication adherence. 15 
Risperidone long-acting injection* (RLAI) is the first injectable, long- 
acting, atypical antipsychotic drug marketed in Canada. 24 The drug is 
administered intramuscularly to the gluteal muscle at a starting dose of 
25 mg and may be increased to 37.5 mg or 50 mg biweekly. A therapeutic 
amount of the medication is released steadily over several weeks. The 
efficacy of RLAI with respect to cognitive functioning (Clinical Global 
Impression-Improvement [CGI-I] Scale, 25 Positive and Negative Symptom 
Scale26), adverse events (Extrapyramidal Symptom Scale), 27 and resource 
utilization (rehospitalization rates, length of stay) has been reported in both 
long- and short-term clinical trials. 1°,28-32 
RLAI has been used at the Vancouver Community Mental Health Or- 
ganization (VCMHO) since the summer of 2005. This pilot study was 
intended to avoid some of the limitations of a tightly control led clinical 
trial to provide a prel iminary assessment of RLAI by retrospect ively exam- 
ining clinical improvement and hospitalization rates in our institution. Its 
purpose was to aid decision makers in pursuing efficient and effective 
treatment of individuals with schizophrenia, schizoaffective disorder, or 
schizophreniform disorder. We hypothesized that t reatment with RLAI 
would be effective in reducing hospital ization rates and improving clinical 
symptoms. 
*Trademark: Risperdal ® Consta ® (Janssen LP, Titusville, New Jersey). 
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PATIENTS AND METHODS 
The study protocol was approved by the VCMHO's research advisory com- 
mittee and ethical approval was received. The study was conducted in accor- 
dance with the Guideline for Good Clinical Practice 33 and the principles of the 
Declaration of Helsinki. 34 
In this naturalistic, retrospective, non-randomized, within-patient study, patients 
served as their own controls. The intervention was the introduction of the atypi- 
cal antipsychotic medication RLAI. Patient demographic characteristics ollected 
included age, gender, diagnosis, and number of previous psychiatric admissions. 
Data were collected via a retrospective chart review of current outpatients 
treated by 1 of the 8 mental health teams in the VCMHO in Vancouver, British 
Columbia, Canada, between August 1, 2006 and September 30, 2006. Male and 
female patients aged 19 to 65 years who were outpatients were eligible for the 
study if they had a diagnosis of schizophrenia, schizoaffective disorder, or 
schizophreniform disorder, according to the Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition 35 criteria. In addition, they had to have been 
started on RLAI treatment during their last hospital inpatient admission and 
had to have continued RLAI treatment for >90 days. 
We used 4 sources of data for the chart review: (1) the physical chart main- 
tained by the patient's mental health team; (2) the patients' case-manager 
interviews; (3) the patient care information system; and (4) the primary access 
regional information system (PARIS). These data sources contained case his- 
tories, hospitalizations, registrations, referrals, assessments, case notes, care 
plans, and scheduling of ongoing treatment information. The last 2 sources 
of data are electronic databases maintained by Vancouver Coastal Health 
(Vancouver, British Columbia, Canada) and the VCMHO. 
The overall severity of symptoms before and after RLAI treatment and the 
improvement in symptoms during treatment were gauged by the CGI-Severity 
(CGI-S) Scale 25 (1 = not ill to 7 = extremely ill) and the CGI-I Scale (1 = very much 
improved to 7 = very much worse), respectively. All ratings were completed by 
a single rater with CGI Scale certification who, because of the nature of this 
retrospective chart review, was not blinded to the patients' treatment. Patients 
were rated according to the assessment and follow-up notes written by the 
treating psychiatrist that were found in the PARIS database, in their medical 
charts, and in their case-manager interviews. 
Data Collection 
A patient medication and history instrument was developed. The instrument 
contained separate sections for the following: (1) frequency, location, and dura- 
tion of institutional care; (2) discharge and relapse rates; (3) demographic vari- 
ables (age, sex, ethnicity, socioeconomic status); (4) diagnosis history (primary 
diagnosis, secondary diagnosis, comorbid conditions); (5) RLAI medication 
history (date of first injection, injection frequency, date of last injection); and 
(6) previous and concurrent antipsychotic medications. 
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The PARIS database was used to generate a list of patients who had received 
RLAI in the VCMHO. The data were collected by a trained research assistant and 
entered into an Access database (Microsoft Corporation, Seattle, Washington). 
As the selection criteria for inclusion in the review were a diagnosis of schizo- 
phrenia, schizoaffective disorder, or schizophreniform disorder and treatment 
with RLAI, data could not be collected in a blind manner. However, all identify- 
ing data were extracted, with each patient's chart being issued a unique code 
number and all information gathered from the chart being identified by this 
number. 
If a significant number of patients had extended psychiatric histories com- 
pared with the length of RLAI treatment, comparing these unequal periods 
could lead to erroneous conclusions. Therefore, a comparison of hospitaliza- 
tion rates during identical periods before and after treatment was calculated. 
Statistical Analysis 
The data were analyzed using a paired Student test and z score for pro- 
portion, depending on the nature and distribution of the data. All data were 
screened for normality, homogeneity of variance, and outliers. Statistical sig- 
nificance was set at P < 0.05. All statistical analyses were conducted using SPSS 
version 14.0 (SPSS Inc., Chicago, Illinois). As this was a preliminary pilot study, 
no power calculation was performed. All data are reported as mean (SD). 
RESULTS 
Forty-four patients were identified as having received treatment with RLAI, and 
19 (10 men, 9 women) of these met the inclusion criteria. The mean (SD) age at 
time of chart audit was 36.7 (11.7) years. The mean age at primary diagnosis of 
schizophrenia was 23.6 (7.4) years, with most patients being white (10 [53%]) 
or Asian (6 [32%]). The majority of patients were diagnosed with schizophrenia 
(13 [68%]), followed by schizoaffective disorder (5 [26%]), and schizophreni- 
form disorder (1 [5%]) (Table I). 
Figure 1 shows the percentage of patients taking other drugs, by drug 
category, before and after treatment with RLAI. Before initiation of RLAI, the 
majority of patients (78%) had been treated with an antipsychotic medica- 
tion, followed by mood stabilizers (39%), antidepressants (28%), sedatives 
(17%), and anticholinergic drugs (28%). The percentage change for each drug 
category before and after commencing RLAI was not found to be significantly 
different. The most common medications prescribed prior to RLAI treatment 
were oral risperidone (77%), quetiapine (47%), zuclopenthixol (43%), olanza- 
pine (43%), and loxapine (17%). 
The mean (SD) RLAI treatment period was 235.6 (162.6) days (Table I). At 
the time of the chart audit, all 19 patients were still receiving RLAI. The number 
of patients receiving 25 mg, 37.5 mg, or 50 mg as a function of their initial dose 
versus final study dose is shown in Figure 2. The majority of patients were 
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Table I. Demographic and clinical characteristics (N = 19). 
Characteristic Value 
Age at time of chart audit, y 
Mean (SD) 36.7 (11.7) 
Range 18-54 
Age at primary diagnosis, y 
Mean (SD) 23.6 (7.4) 
Range 16-44 
Race, no. (%) 
White 10 (52.6) 
Asian 6 (31.6) 
American Indian 1 (5.3) 
Black 1 (5.3) 
Other 1 (5.3) 
Primary diagnosis, no. (%) 
Schizophrenia 13 (68.4) 
Schizoaffective disorder 5 (26.3) 
Schizophreniform disorder 1 (5.3) 
Duration of RLAI therapy, d 
Mean (SD) 235.6 (162.6) 
Range 94-771 
RLAI = risperidone long-acting injection. 
receiving a dose of 25 mg at both initial t reatment and final study treatment.  
Although there was a shift in the number of patients receiving differing initial 
and final doses of RLAI, the differences were not statistically significant. 
Pretreatment initiation and posttreatment initiation RLAI CGI-S Scale scores 
were examined using a paired t test. Two patients were excluded from the 
analysis due to insufficient case notes to calculate a CGI-S or CGI-I score. The 
mean (SD) CGI-S score declined significantly from 5.29 (1.3) to 3.05 (1.0) (t16 = 
7.36; P < 0.001), indicating a movement from the severe range to the mild range 
(Figure 3). Mean CGI-I score suggested an overall improvement (2.58 [0.71]). 
Using a categorical definition of CGI-I of <3, 16 of the 17 patients (94%) showed 
improvement (z = 8.8; P < 0.001). 
Treatment with RLAI was well tolerated, and no serious adverse events 
(AEs) were observed. Three patients (15.8%) exper ienced AEs (sedation 
[1 patient], impotence [1], and akathisia [1]). Prolactin concentration, Abnormal 
Involuntary Movement Scale (AIMS) scores, and weight measurements were 
not available at the time of the chart  audit. 
A significant number of patients (84%) had extended psychiatric histories 
in comparison to the length of their RLAI treatment.  Because comparison of 
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Figure 1. Percentage of patients with a schizophrenia spectrum illness receiving 
treatment with other drugs prior to and during treatment with risperidone 
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Figure 2. Initial and final doses in patients with a schizophrenia spectrum illness 
treated with risperidone long-acting injection (N =19). 
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Figure 3. Mean pretreatment initiation and posttreatment initiation Clinical Global 
Impression-Severity (CGI-S) and CGl-lmprovement (CGI-I) Scale scores in 
patients with a schizophrenia spectrum illness treated with risperidone 
long-acting injection (N = 19). *P < 0.001 versus pretreatment. 
these unequal periods might have led to erroneous results, a comparison of 
hospitalization rates during identical periods before and after treatment was 
calculated. For each patient, the duration of the pre-RLAI assessment period 
was defined by the duration of t reatment with RLAI. The hospitalization data 
were examined using a paired Student test. The mean (SD) duration of hos- 
pitalization decreased from 15.7 (19.7) to 2.4 (6.0) days (t18 = 2.78; P < 0.05). 
Similarly, the mean number of psychiatric hospitalizations decreased from 2.0 
(1.8) before RLAI treatment to 0.5 (1.3) after RLAI t reatment ( 18 = 2.89; P < 0.01) 
(Table II). 
Table II. Psychiatric hospitalizations. 
Pre-RLAI Post-RLAI 
(n= 19) (n= 19) t18 P* 
Duration of psychiatric 
hospitalizations, 
mean (SD), d 15.7 (19.7) 2.4 (6.0) 2.78 <0.05 
Psychiatric hospitalizations, 
mean (SD), no. 2.0 (1.8) 0.53 (1.3) 2.89 <0.01 
RLAI = risperidone long-acting injection. 
*Paired 2-tailed Student t test. 
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DISCUSSION 
In a systematic chart review of all patients with a clinical diagnosis of schizo- 
phrenia, schizoaffective disorder, or schizophreniform disorder treated with 
RLAI in the VCMHO, we found a moderate response in controlling symptoms 
in the majority of these patients. There were clinically relevant and statisti- 
cally significant improvements in disease state and functioning, as measured 
by the CGI-S and CGI-I Scale scores. Pretreatment initiation and posttreatment 
initiation CGI-S ratings for RLAI treatment suggested a statistically significant 
movement from the severe (5.29 [1.3]) to the mild (3.05 [1.0]) range and were 
consistent with previously published studies. 3°,36-43 Similarly, CGI-I scores 
showed an overall positive result (mean score, 2.58 [0.71]), with 94% of patients 
scoring <3. The clinical improvement was also noted by case managers and 
considered to be high quality. 
The number of hospitalizations and the duration of hospitalization have been 
suggested to be indicators of relapse. 2 During treatment with RLAI, the total 
mean duration of hospitalization decreased from 15.7 (19.7) days to 2.4 (6.0) days 
and the mean number of hospitalizations decreased from 2.0 (1.8) to 0.53 (1.3). 
Despite the limited total mean duration of RLAI treatment (235.6 [162.6] days), 
these findings suggest hat there was a reduction in patient relapse. 
RLAI treatment was well-tolerated, with no reports of serious AEs. The most 
common AEs were sedation, impotence, and akathisia, reported in 1 patient 
each. Sedation was considered mild and well-tolerated. The severity of AEs, as 
measured by AIMS or Extrapyramidal Side Effect Rating Scale, were unavail- 
able, as were the relationship of AEs to dose. Although weight gain is gener- 
ally modest in patients taking RLAI, it can be significant in a minority of these 
patients. 32,4°,44,45 Unfortunately, in the present review, weight was not ade- 
quately quantified to allow for analysis. 
Limitations 
The data presented were derived from a retrospective chart review and, 
as such, were subject o observation and assessment bias. In addition, 22% of 
patients had not been treated with an antipsychotic drug prior to RLAI treat- 
ment. This might have exaggerated the positive effects of RLAI treatment. 
Other limitations include a lack of AE data and CGI ratings that were calculated 
by only 1 rater, which might have introduced single-rater bias. Despite the 
inherent limitations of chart reviews, such data are needed to begin to for- 
mulate hypotheses regarding the potential therapeutic use of new treatment 
approaches, uch as RLAI for schizophrenia, in a community mental health set- 
ting. The results were cautiously encouraging and indicated the need for more 
prospective controlled trials with RLAI. 
The data presented in this study suggest hat the majority of patients initi- 
ated on RLAI remained on stable doses with high continuation rates along with 
concomitant medication. Long-term data with larger sample size are being 
accrued to further explore these outcomes over time. 
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CONCLUSIONS 
The results of this pilot study suggest that use of the atypical antipsychotic medica- 
tion RLAI significantly decreased uration and rates of hospitalization, compared 
with baseline, in these VCMHO patients with schizophrenia spectrum illnesses. 
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